Clinical Trial Update: A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial of GSK2110183 in proteasome inhibitor refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GSK2110183

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 2 | Status: WITHDRAWN